Aripiprazole for late-life schizophrenia

Abstract

Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high co-morbidity rates (both psychiatric and medical) in the elderly; age-related changes in pharmacokinetics leading to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia and other psychotic conditions, focusing on the potential role of aripiprazole.

Keywords:

• aripiprazole
• schizophrenia
• elderly
• dopamine partial antagonist

Disclosure

Philip Janicak Grant/Reasearch: Otsuka, Neuronetics; Advisor/Consultant: Bristol Myers Squibb, Neuronetics, Takeda; Speakers’ Bureau: Astra Zeneca, Bristol Myers Squibb/Otsuka, Janssen, Neuronetics, Novartis. Jeffrey Rado Research/Grant: Otsuka, Neuronetics, Lilly Speakers Bureau: Lilly.